SB 1545 would prohibit pharmacy benefit managers (PBMs) from acquiring or holding a direct or indirect interest in a pharmacy permit issued under Arizona law for the retail sale of prescription drugs. In practical terms, the bill is aimed at separating PBM ownership or control from retail pharmacy permitting, and it directs the Arizona State Board of Pharmacy to revoke or refuse to renew any permit held in violation of the new restriction.
The bill amends Title 32, Chapter 18 of the Arizona Revised Statutes by adding a new section governing pharmacy permits and PBMs. It also contemplates board rules, limited service pharmacy permits, exceptions, and notification requirements, although the text provided only expressly states the core prohibition and enforcement mechanism. The measure would affect PBMs, retail pharmacies, and the Board of Pharmacy by changing who may lawfully hold a permit to sell prescription drugs in the state.
Impact
SB 1545 would create a new statutory restriction in Arizona pharmacy law by barring pharmacy benefit managers from owning or otherwise controlling retail pharmacy permits. It would require the Arizona State Board of Pharmacy to take action against any permit held in violation of the new rule, including revocation or nonrenewal, thereby directly affecting existing permit holders and future applicants with PBM ties. The bill would likely influence corporate ownership structures, pharmacy network arrangements, and the relationship between PBMs and retail drug dispensing operations.
Sentiment
There is no recorded committee testimony or vote history in the provided materials, so no formal public sentiment can be measured from the transcript record. Based on the bill text alone, the measure appears to reflect a policy concern about PBMs having ownership interests in retail pharmacies, suggesting a reform-oriented or anti-consolidation posture. Because no discussion or votes are available, support and opposition cannot be reliably characterized beyond the bill’s apparent intent.
Contention
The likely point of contention is whether PBMs should be allowed to own or control retail pharmacy permits at all. Supporters would likely argue the bill reduces conflicts of interest and limits vertical integration in the prescription drug market, while opponents may argue it restricts business models, could reduce efficiency, and may disrupt existing ownership arrangements. The bill also leaves open questions about how exceptions, limited service permits, and notification requirements would be implemented through board rules.